Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-3-96396036
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.13 million
Profitability
Miscellaneous
Employees81
Next Earnings Date2/19/2020 (Estimated)
OptionableOptionable
Mesoblast (ASX:MSB) Frequently Asked Questions
What is Mesoblast's stock symbol?
Mesoblast trades on the ASX under the ticker symbol "MSB."
How were Mesoblast's earnings last quarter?
Mesoblast limited (ASX:MSB) issued its quarterly earnings data on Thursday, February, 21st. The company reported ($0.09) earnings per share for the quarter. View Mesoblast's Earnings History.
When is Mesoblast's next earnings date?
Has Mesoblast been receiving favorable news coverage?
News headlines about MSB stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mesoblast earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Mesoblast.
Who are some of Mesoblast's key competitors?
Some companies that are related to Mesoblast include MorphoSys (MOR), MorphoSys (MOR), Cronos Group (CRON), BTG (BTG), Abcam (ABC), Kodiak Sciences (KOD), Genus (GNS), Polynovo (PNV), Vir Biotechnology (VIR), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), CEL-SCI (CVM) and Cel-Sci (CVM).
What other stocks do shareholders of Mesoblast own?
Who are Mesoblast's key executives?
Mesoblast's management team includes the folowing people:
- Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
- Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
- Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
- Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
- Dr. Kenneth M. Borow M.D., Exec. (Age 71)
What is Mesoblast's stock price today?
One share of MSB stock can currently be purchased for approximately A$2.70.
How big of a company is Mesoblast?
What is Mesoblast's official website?
How can I contact Mesoblast?
Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036.
MarketBeat Community Rating for Mesoblast (ASX MSB)
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MSB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MSB will underperform the S&P 500 over the long term. You may vote once every thirty days.
